Beijing Health Updates Nomination Committee Mandate to Strengthen Board Governance

Beijing Health (Holdings) Limited ( (HK:2389) ) has provided an announcement.

Beijing Health (Holdings) Limited has amended and restated the terms of reference of its Nomination Committee with effect from 30 March 2026, refining its composition, meeting procedures and governance arrangements. The committee must comprise at least three members, with a majority being independent non-executive directors, at least one member of a different gender, and is required to meet at least once a year, with detailed rules on quorum, voting, minute-taking and attendance at annual general meetings.

The updated mandate formalizes the committee’s responsibilities to formulate and implement board nomination policy, annually review the board’s structure, size and diversity, and identify and recommend director candidates based on merit and objective criteria. By explicitly emphasizing gender and broader diversity, as well as alignment of board skills with corporate strategy, the changes aim to strengthen the company’s corporate governance framework and provide shareholders with more transparent and structured oversight of board appointments.

The most recent analyst rating on (HK:2389) stock is a Hold with a HK$0.06 price target. To see the full list of analyst forecasts on Beijing Health (Holdings) Limited stock, see the HK:2389 Stock Forecast page.

More about Beijing Health (Holdings) Limited

Beijing Health (Holdings) Limited is a Hong Kong-listed company incorporated in the Cayman Islands and traded under stock code 2389. The group operates under Hong Kong’s Listing Rules and is governed by a board structure that includes executive and independent non-executive directors, reflecting standard corporate governance practices for listed issuers.

Average Trading Volume: 1,452,137

Technical Sentiment Signal: Sell

Current Market Cap: HK$393.8M

Learn more about 2389 stock on TipRanks’ Stock Analysis page.